PMID- 32155941
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar 6
TI  - Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When 
      Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive 
      Advanced Breast Cancer.
LID - 10.3390/cancers12030617 [doi]
LID - 617
AB  - Background: Single-agent capecitabine (C) is a moderately effective 
      chemotherapeutic compound in the treatment of patients with HER2-negative 
      metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is 
      also used due to a good tolerability profile, but no studies have demonstrated 
      its superiority over single-agent C. Methods: We conducted a retrospective 
      analysis to compare overall response rate (ORR), progression-free survival (PFS), 
      overall survival (OS) and incidence of adverse events (AEs) in patients with 
      HER2-negative mBC treated with CV vs. single-agent C. Results: Out of 290 
      patients included in this study, 127 (43.8%) received single-agent C, while 163 
      (56.2%) patients were treated with CV. Median PFS was similar in patients treated 
      with single-agent C or CV, while CV was associated with significantly longer OS 
      in patients with hormone receptor-positive (HR+) BC. This OS advantage was 
      confirmed at multivariable analysis also after propensity score-based matching of 
      patients according to relevant clinical or tumor characteristics. When compared 
      with single-agent C, CV was associated with higher incidence of G3/G4 and 
      any-grade nausea/vomiting, diarrhea and increased transaminases. Conclusions: 
      While prospective studies are needed to confirm our findings, the potential OS 
      advantage of CV over single-agent C in HR+ mBC patients must be weighed against a 
      significantly higher incidence of AEs.
FAU - Vernieri, Claudio
AU  - Vernieri C
AD  - Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Via Adamello 16, 20133 
      Milan, Italy.
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Prisciandaro, Michele
AU  - Prisciandaro M
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Nichetti, Federico
AU  - Nichetti F
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Lobefaro, Riccardo
AU  - Lobefaro R
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Peverelli, Giorgia
AU  - Peverelli G
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Ligorio, Francesca
AU  - Ligorio F
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Zattarin, Emma
AU  - Zattarin E
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Cona, Maria Silvia
AU  - Cona MS
AD  - ASST Fatebenefratelli Sacco - PO Luigi Sacco, Milan, Italy, Via G.B. Grassi 74, 
      20133 Milan, Italy.
FAU - Sepe, Pierangela
AU  - Sepe P
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Corti, Francesca
AU  - Corti F
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Manglaviti, Sara
AU  - Manglaviti S
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Brambilla, Marta
AU  - Brambilla M
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Re, Barbara
AU  - Re B
AD  - SC Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 
      20133 Milan, Italy.
FAU - Belfiore, Antonino
AU  - Belfiore A
AD  - Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS 
      Istituto Nazionale dei Tumori, 20133 Milan, Italy.
FAU - Pruneri, Giancarlo
AU  - Pruneri G
AD  - Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS 
      Istituto Nazionale dei Tumori, 20133 Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, 20133 Milan, 
      Italy.
FAU - Celio, Luigi
AU  - Celio L
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Mariani, Gabriella
AU  - Mariani G
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Bianchi, Giulia Valeria
AU  - Bianchi GV
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - Rivoltini, Licia
AU  - Rivoltini L
AD  - Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei 
      Tumori, 20133 Milan, Italy.
FAU - Capri, Giuseppe
AU  - Capri G
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
FAU - de Braud, Filippo
AU  - de Braud F
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133 Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, 20133 Milan, 
      Italy.
LA  - eng
GR  - MFAG 2019 -22977/Associazione Italiana per la Ricerca sul Cancro/
GR  - D18CV/Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori/
PT  - Journal Article
DEP - 20200306
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7139362
OTO - NOTNLM
OT  - advanced breast cancer
OT  - adverse events
OT  - capecitabine
OT  - chemotherapy
OT  - hormone receptor-positive breast cancer
OT  - overall survival
OT  - progression-free survival
OT  - triple-negative breast cancer
OT  - vinorelbine
COIS- The authors declare no conflict of interest.
EDAT- 2020/03/12 06:00
MHDA- 2020/03/12 06:01
PMCR- 2020/03/06
CRDT- 2020/03/12 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/02/27 00:00 [revised]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/03/12 06:00 [entrez]
PHST- 2020/03/12 06:00 [pubmed]
PHST- 2020/03/12 06:01 [medline]
PHST- 2020/03/06 00:00 [pmc-release]
AID - cancers12030617 [pii]
AID - cancers-12-00617 [pii]
AID - 10.3390/cancers12030617 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Mar 6;12(3):617. doi: 10.3390/cancers12030617.